ZIM
ACHN

Zacks Investment Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Zacks Investment Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-109,647
Closed -$453K – 768
2016
Q4 		$453K Buy
109,647
+29,692
+37% +$158K 0.01% 453
2016
Q3 		$648K Sell
79,955
-2,704
-3% -$23K 0.02% 420
2016
Q2 		$645K Sell
82,659
-4,383
-5% -$37.6K 0.02% 414
2016
Q1 		$672K Hold
87,042
– – 0.02% 404
2015
Q4 		$939K Buy
+87,042
New +$791K 0.03% 307
2015
Q2 		– Sell
-36,418
Closed -$359K – 760
2015
Q1 		$359K Buy
+36,418
New +$455K 0.01% 480

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Zacks Investment Management's ACHN Position: Q1 2017 in Review

Zacks Investment Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2017, closing a stake of 109,647 shares — an estimated $453K sold.

Zacks Investment Management first reported a position in ACHN in Q1 2015 and held it in 6 quarters. The position peaked at $939K in Q4 2015. 130 funds tracked by Wall St. Rank hold ACHN as of Q1 2017.

  • Zacks Investment Management reported no remaining Achillion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Zacks Investment Management sold 109,647 Achillion Pharmaceuticals shares in Q1 2017, an estimated $453K.
  • Zacks Investment Management first reported a position in Achillion Pharmaceuticals in Q1 2015 and held it in 6 quarters.
  • Zacks Investment Management's Achillion Pharmaceuticals position peaked at $939K in Q4 2015.
  • 130 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2017.

Based on Zacks Investment Management's 13F filing for Q1 2017, filed 15 May 2017.